Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence

Bibliography

• Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev 2011;6:CD008537
   PubMedGoogle Scholar
• Minozzi S, Amato L, Vecchi S, Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2010;3:CD005064
   PubMedGoogle Scholar
• Muzyk AJ, Fowler JA, Norwood DK, Role of a2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother 2011;45:649-57
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2011;1:CD008502
   PubMedGoogle Scholar
• Jorgensen CH, Pedersen B, Tonnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011;35:1749-58
   PubMed Web of Science ®Google Scholar
• Hillemacher T, Heberlein A, Muschler MAN, Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 2011;20:1073-86
   PubMed Web of Science ®Google Scholar
• Witkiewitz K, Saville K, Hamreus K. Acamposate for treatment of alcohol dependence: mechanisms, efficacy and clinical utility. Ther Clin Risk Manag 2012;8:45-53
   PubMed Web of Science ®Google Scholar
• Soyka M, Rosner S. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs 2010;19:1451-8
   PubMed Web of Science ®Google Scholar
• Roache JD, Wang Y, Ait-Daoud N, Prediction of serotonergic treatment- efficacy using age of onset and type A/B typologies of alcoholism. Alcohol Clin Exp Res 2008;32:1502-11
   PubMed Web of Science ®Google Scholar
• Kenna GA, Lomastro TL, Schiesl A, Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009;2:135-42
   PubMedGoogle Scholar
• Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010;16:2113-17
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 2007;33:393-401
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Di Giannantonio M. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial versus naltrexone. J Psychopharmacol 2009;23:123-9
   PubMed Web of Science ®Google Scholar
• Denis C, Fatseas M, Lavie E, Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005194
   PubMedGoogle Scholar
• Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006;7:2139-54
   PubMed Web of Science ®Google Scholar
• Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006;20:685-93
   PubMed Web of Science ®Google Scholar
• Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (Barc) 2007;43:601-10
   PubMed Web of Science ®Google Scholar
• Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007;7:769-81
   PubMedGoogle Scholar
• Bandelow B, Zohar J, Hollander E, WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry 2008;9:248-312
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Taylor CP, Donevan S, Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82
   PubMed Web of Science ®Google Scholar
• Li Z, Taylor CP, Weber M, Pregabalin is a potent and selective ligand for a2d-1 and a2d-2 calcium channel subunits. Eur J Pharmacol 2011;667:80-90
   PubMed Web of Science ®Google Scholar
• Carlson JM, Greenberg T, Rubin D, Feeling anxious: anticipatory amygdalo-insular response predicts the feeling of anxious anticipation. Soc Cogn Affect Neurosci 2011;6:74-81
   PubMed Web of Science ®Google Scholar
• Aupperle RL, Ravindran L, Tankersley D, Pregabalin influences insula and amygdale activation during anticipation of emotional images. Neuropsychopharmacology 2011;36:1466-77
   PubMed Web of Science ®Google Scholar
• Wang Z, Pang RD, Hernandez M, Anxiolytic-like effect of pregabalin on unconditioned fear in the rat: an autoradiographic brain perfusion mapping and functional connectivity study. NeuroImage 2011; published online 1 December, doi:10.1016/j.neuroimage.2011.11.047
   Web of Science ®Google Scholar
• Siok CJ, Taylor CP, Hajos M. Anxiolytic profile of pregabaline on elicited hippocampal theta oscillation. Neuropharmacology 2009;56:379-85
   PubMed Web of Science ®Google Scholar
• Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006;16(Suppl 2):S128-33
   PubMed Web of Science ®Google Scholar
• Shneker BF, Mc Auley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029-37
   PubMed Web of Science ®Google Scholar
• Stopponi S, Somaini L, Cippitelli A, Pragabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology 2011: published online 2 September 2011, doi:10.1007/s00213-011-2457-3
   PubMed Web of Science ®Google Scholar
• Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol 2006;4:399-406
   Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008;25:608-18
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, Pregabalin versus naltrexone in alcohol dependence: a randomized, double-blind, comparison trial. J Psychopharmacol 2010;24:1367-74
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Martinotti G, Tedeschi D, Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol Clin Exp 2010;25:268-75
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Frustaci A, Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-center, randomized, single-blind comparison trial. Addiction 2010;105:288-99
   PubMed Web of Science ®Google Scholar
• Forg A, Hein J, Volkmar K, Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized, placebo-controlled trial. Alcohol Alcohol 2012: published online 2 January 2012, doi: 10.1093/alcalc/agr153
   PubMedGoogle Scholar
• Biermann T, Bleich S, Kornhuber J, Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry 2007;40:292-3
   PubMed Web of Science ®Google Scholar
• Oulis P, Masdrakis VG, Karakatsanis NA, Pregabalin in the discontinuation of long-term benzodiazaepine-use: a case series. Int Clin Psychopharmacol 2008;23:110-12
   PubMed Web of Science ®Google Scholar
• Oulis P, Konstantakopoulos G, Kouzoupis AV, Pregabalin in the discontinuation of benzodiazepine-use. Hum Psychopharmacol 2008;23:337-40
   PubMed Web of Science ®Google Scholar
• Bramness JG, Sandvik P, Engeland A, Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison withb gabapentin using the Norvegian prescription database. Basic Clin Pharmacol Toxicol 2010;107:88-6
   Google Scholar
• Bobes J, Rubio G, Teran A, Pregabalin for the discontinuation of long-term benzodiazepine use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 2011, published online 18 February 2011, doi:10.1016/j.eurpsy.2010.12.004
   Web of Science ®Google Scholar
• Rubio G, Bobes J, Cervera G, Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur Addict Res 2011;17:262-70
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP, Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in post-herpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84
   PubMed Web of Science ®Google Scholar
• Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2011, published online 21 June 2011, doi:10.1177/0269881111405360
   PubMed Web of Science ®Google Scholar
• Oulis P, Nakkas G, Masdrakis VG. Pregabalin in Zolpidem Dependence and Withdrawal. Clin Neuropharm 2011;34:90-1
   PubMed Web of Science ®Google Scholar
• Wustmann T, Piro J, Gutmann P. Metabolic considerations in a case of pregabalin-induced edema. Pharmacopsychiatry 2009;42:75-6
   PubMed Web of Science ®Google Scholar
• Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011;45:e32
   PubMedGoogle Scholar
• Einarsdottir S, Bjornsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008;20:1049
   PubMed Web of Science ®Google Scholar
• Dogan S, Ozberk S, Yursi A. Pregabalin-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2011;23:628
   PubMed Web of Science ®Google Scholar
• Anonymous. Abuse of pregabalin exists, but it's uncertain how often. Lakartidningen 2011;108:1501
   PubMedGoogle Scholar
• Smith TL, Baldwin A, Cunningham LL, Rash associated with pregabalin use. Ann Pharmacother 2008;42:1899-901
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, The adverse event-profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005;70:43633-5
   PubMedGoogle Scholar
• Raza S, Siddiqui UA, Megna JL, Pregabalin treatment of anxiety in patients with substance use disorder. Ann Pharmacother 2010;44:937-8
   PubMed Web of Science ®Google Scholar
• Grosshans M, Mutschler J, Hermann D, Pregabalin abuse, dependence and withdrawal: a case-report. Am J Psychiatry 2010;167:869
   PubMed Web of Science ®Google Scholar
• Filipetto FA, Zipp CP, Cohen JS. Potential of pregabalin abuse or diversion after past drug-seeking behavior: case-report. JAOA 2010;110:605-7
   Google Scholar
• Yargic I, Ozdemiroglu FA. Pragabalin abuse: a case-report. Bull Clin Psychopharmacol 2011;21:64-6
   Web of Science ®Google Scholar
• Landmark CJ, Fossmark H, Larson PG, The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen 2011;131:223
   PubMedGoogle Scholar
• Westin AA, Strom EJ. Yes, pregabalin can be abused! Tidsskr Nor Laegeforen 2010;130:2108
   PubMedGoogle Scholar
• Bramness JG. Abuse of pregabalin. Tidsskr Nor Laegeforen 2010;130:1703-4
   PubMedGoogle Scholar
• Chalabianloo F, Scjott J. Abuse of pregabalin. Tidsskr Nor Laegeforen 2009;129:186-7
   PubMedGoogle Scholar
• Schifano F, Leoni M, Martinotti G, Importance of cyberspace for the assessment of the drug-abuse market: preliminary results from the Psychonaut 2002 project. Cberpsychol Behav 2003;6:405-10
   PubMedGoogle Scholar
• Schifano F, Deluca P, Agosti L, New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 (“Blue Mystic”). J Psychopharmacol 2005;19:675-9
   PubMed Web of Science ®Google Scholar
• Schifano F, D'Offizi S, Piccione M, Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011;80:118-22
   PubMed Web of Science ®Google Scholar
• Schwan S, Sundstroem A, Stjernberg E, A signal for an abuse liability for pregabalin: results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010;66:947-53
   PubMed Web of Science ®Google Scholar
• Zacny JP, Paice JA, Calson DW. Subjective, psychomotor and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 2012;100:560-5
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology 2005;183:133-43
   PubMed Web of Science ®Google Scholar
• Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010;74:755-61
   PubMed Web of Science ®Google Scholar